Gilead Sciences: PharmaVitae Profile

Introduction
This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
Gain insight into Gilead's strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Gilead over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered
Benchmark Gilead's performance against key rivals in the prescription pharmaceutical sector
Assess the effects of the patent expiry of one of the components of Atripla on the company
See how the launch of two new products, Truvada + rilpivirine and the Quad pill, will generate new growth for the company

[Studien Infos ausblenden]

TABLE OF CONTENTS
About Datamonitor Healthcare 2
About the PharmaVitae team 2
Chapter 1 About This Profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive Summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 7
Gilead: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 14
Chapter 3 Quarterly News Update 22
Latest quarterly sales 22
Latest comment 22
Latest prescription pharma product news 25
Latest corporate news 28
Future product milestones 30
Chapter 4 Company Introduction 31
Key findings 31
Background 31
Key corporate developments 31
M&A history 32
Chapter 5 Company Sales 34
Key findings 34
Prescription pharmaceutical sales and growth rate analysis, 2003–15 35
Product analysis 37
Therapy area analysis 43
Geographic analysis 45
Launch/core/expiry analysis 47
Molecule type analysis 52
Externalization analysis 54
Chapter 6 Company Financials 57
Key findings 57
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 58
Operating costs and profit analysis 59
Chapter 7 Key Products 66
Key findings 66
Overview 67
Chapter 8 Appendix 78
References 78
Abbreviations 78
About Datamonitor 78
Datamonitor consulting 79
Disclaimer 81


TABLE OF TABLES
Table 1: Gilead – PharmaVitae forecasts at a glance 8
Table 2: Gilead’s HIV franchise, 2009–15 ($m) 10
Table 3: HIV market share, 2009–15 ($m) 12
Table 4: Gilead quarterly sales ($m), Q4 2008–Q4 2009 22
Table 5: Gilead future product milestones, 2010–12 30
Table 6: Gilead product portfolio overview ($m), 2003–09 38
Table 7: Gilead product portfolio overview ($m), 2009–15 40
Table 8: Gilead prescription pharmaceutical sales, by therapy area ($m), 2009–15 44
Table 9: Gilead prescription pharmaceutical sales, by geographic region ($m), 2009–15 46
Table 10: Gilead launch portfolio overview ($m), 2009–15 48
Table 11: Gilead core portfolio overview ($m), 2009–15 49
Table 12: Gilead expiry portfolio overview ($m), 2009–15 50
Table 13: Gilead prescription pharmaceutical sales, by molecule type ($m), 2009–15 53
Table 14: Gilead prescription pharmaceutical sales, by source ($m), 2009–15 55
Table 15: Total Gilead sales, by business unit ($m), 2003–09 58
Table 16: Gilead operating revenue/cost analysis ($m), 2003–09 61
Table 17: Gilead operating cost ratio analysis (% of total revenues), 2003–09 62
Table 18: Gilead operating cost ratio analysis (% of total revenues), 2009–15 63
Table 19: Gilead operating revenue/cost analysis ($m), 2009–15 64
Table 20: Gilead key products overview 67
Table 21: Truvada + rilpivirine overview 68
Table 22: Truvada + rilpivirine sales forecast ($m), 2009–15 69
Table 23: Quad pill overview 71
Table 24: Quad pill sales forecast ($m), 2009–15 72
Table 25: Truvada overview 73
Table 26: Truvada sales forecast ($m), 2009–15 74
Table 27: Atripla overview 76
Table 28: Atripla sales forecast ($m), 2009–15 77


TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 6
Figure 3: Gilead operating revenue/cost analysis ($m), 2003–15 7
Figure 4: Operating profit margin comparison, 2009–15 13
Figure 5: Gilead SWOT analysis 14
Figure 6: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 35
Figure 7: Gilead key product sales ($m), 2003–15 37
Figure 8: Gilead key sales growth drivers and resistors ($m), 2003–09 39
Figure 9: Gilead key sales growth drivers and resistors ($m), 2009–15 41
Figure 10: Gilead prescription pharmaceutical sales, by therapy area ($m), 2003–15 43
Figure 11: Gilead prescription pharmaceutical sales, by geographic region ($m), 2003–15 45
Figure 12: Gilead launch/core/expiry configuration ($m), 2009–15 51
Figure 13: Gilead prescription pharmaceutical sales, by molecule type ($m), 2003–15 52
Figure 14: Gilead prescription pharmaceutical sales, by source ($m), 2003–15 54
Figure 15: Gilead operating revenue/cost analysis ($m), 2003–15 60


[Inhaltsverzeichnis ausblenden]